Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: Data from the BEVORDEX randomised clinical trial

British Journal of Ophthalmology

Volumn 100, Issue 7, 2016, Pages 1000-1004

  Mehta, Hemal ^a,b   Fraser Bell, Samantha ^a   Yeung, Aaron ^a   Campain, Anna ^a   Lim, Lyndell L ^c   Quin, Godfrey J ^a,d   McAllister, Ian L ^e   Keane, Pearse A ^b   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MACULAR HARD EXUDATE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETINA EXUDATE; TREATMENT DURATION; TREATMENT PLANNING; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DOSE RESPONSE; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84978245518     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-307797     Document Type: Article

References (24)

1. Zhang X, Zeng H, Bao S, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014;4:27
2. Sigurdsson R, Begg IS. Organised macular plaques in exudative diabetic maculopathy. Br J Ophthalmol 1980;64:392-7
3. Takaya K, Suzuki Y, Mizutani H, et al. Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy. Retina 2004;24:23-9
4. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic macular oedema-complications and visual outcome. Acta Ophthalmol Scand 2000;78:667-71
5. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997;115:873-7
6. Larsson J, Kifley A, Zhu M, et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol 2009;87:275-80
7. Domalpally A, Ip MS, Ehrlich JS. Effects of Intravitreal Ranibizumab on Retinal Hard Exudate in Diabetic Macular Edema: Findings from the RIDE and RISE Phase III Clinical Trials. Ophthalmology 2015;122:779-86
8. Gillies MC, Lim LL, Campain A, et al. A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema: The BEVORDEX Study. Ophthalmology 2014;121:2473-81
9. Sasaki M, Kawasaki R, Noonan JE, et al. Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest Ophthalmol Vis Sci 2013;54:5544-50
10. Sim DA, Keane PA, Fung S, et al. Quantitative analysis of diabetic macular ischemia using optical coherence tomography. Invest Ophthalmol Vis Sci 2014;55:417-23
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74
12. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2012: ISBN 3-900051-07-0
13. Csaky KG, Richman EA, Ferris FL III. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008;49:479-89
14. Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis 2015;6:234-45
15. Gillies MC, Islam FM, Larsson J, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clin Experiment Ophthalmol 2010;38:605-12
16. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84
17. Yanoff M. Ocular pathology of diabetes mellitus. Am J Ophthalmol 1969;67:21-38
18. Cusick M, Chew EY, Chan C-C, et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003;110:2126-33
19. Gelman SK, Freund KB, Shah VP, et al. THE PEARL NECKLACE SIGN: a novel spectral domain optical coherence tomography finding in exudative macular disease. Retina 2014;34:2088-95
20. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-58
21. Muni RH, Kohly RP, Lee EQ, et al. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol 2013;131:514-21
22. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005;353:839-41
23. Ciulla TA, Walker JD, Fong DS, et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 2004;15:211-20
24. Wells JA, Glassman AR, Ayala AR, Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203